Clinical trials: in Papua New Guinea
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Drug Pharmacokinetics in Healthy Volunteers
Postpartum 8-aminoquinoline Breast Milk Study
In Papua New Guinea, administration of primaquine (PQ) or tafenoquine (TQ) to breastfeeding mothers is contraindicated during the first six months postpartum, when infants are recommended to be exclusively breastfed, because of a…
- Trial name
- NCT07060404
- Testing
- Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
- Where
- Papua New Guinea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Curtin University
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Malaria, Malaria in Pregnancy
Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) plus dihydroartemisinin-piperaquine (DP) significantly reduces the risk of malaria infection (primary…
- Conditions
- Malaria, Malaria in Pregnancy, Pregnancy Related
- Trial name
- SAPOT (NCT05426434)
- Testing
- Dihydroartemisinin-Piperaquine (DP), Sulfadoxine pyrimethamine (SP)
- Where
- Papua New Guinea
- Volunteers
- 1,172 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Newborn Vaccine Immunogenicity
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use.
- Trial name
- EPIC-HIPC (NCT03246230)
- Testing
- Hepatitis B vaccine (HBV), Bacillus Calmette-Guérin (BCG)
- Where
- 2 sites in Papua New Guinea, The Gambia
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Iodine Deficiency
Estimating Usual Iodine Intake From Spot Urinary Iodine Concentrations
The overall objective of this study is to develop a reliable method to obtain habitual iodine intakes from spot urinary iodine concentration (UIC) and to assess the prevalence of inadequate iodine intake in school-age children…
- Trial name
- ITURN (NCT03602404)
- Where
- 2 sites in Papua New Guinea, Russia
- Volunteers
- 1,592 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Yaws
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases…
- Trial name
- NCT03490123
- Testing
- R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin
- Where
- Papua New Guinea
- Volunteers
- 56,000 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB…
- Trial name
- NCT02899936
- Testing
- 3 drug dose - IDA, 2 drug dose - DA
- Where
- 4 sites in Haiti, India and 2 more
- Volunteers
- 23,789 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
The standard regimen for elimination of lymphatic filariasis (LF) in PNG is annual administration of two drugs at the same time.
- Trial name
- MDA (NCT03268252)
- Where
- Papua New Guinea
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariasis, Yaws
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a Pharmacokinetic and Pharmacodynamic study evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF.
- Conditions
- Lymphatic Filariasis, Yaws, Trauma
- Trial name
- NCT03664063
- Testing
- Azithromycin, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Plasmodium Vivax Malaria
Papua New Guinean Duffy Negativity And Vivax Malar
The purpose of this study is to learn more about vivax malaria in very young children, how the growth of children is affected by malaria infections, and how inherited traits protect children from getting malaria.
- Trial name
- NCT00138489
- Where
- Papua New Guinea
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to…
- Trial name
- NCT01975441
- Testing
- Diethylcarbamazine, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Malaria
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
Mass drug administration with antimalarial treatment is a tool that can potentially reduce or totally eliminate malaria parasite infections from a population.
- Trial name
- ECG-Lihir (NCT02605720)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- Papua New Guinea
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Pregnancy, Infections, Plasmodia
A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women
Plasmodium falciparum parasitaemia in pregnancy is associated with maternal anaemia, low birth-weight and increased perinatal mortality.
- Conditions
- Pregnancy, Infections, Plasmodia, Drug Kinetics, Clinical Efficacy
- Trial name
- NCT02575755
- Testing
- Azithromycin plus piperaquine phosphate, Sulfadoxine-pyrimethamine
- Where
- Papua New Guinea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of…
- Conditions
- Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection, Plasmodium Falciparum Clinical Episode
- Trial name
- NCT02143934
- Testing
- Primaquine, Chloroquine, Artemether Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Pneumonia, Meningitis
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper…
- Conditions
- Pneumonia, Meningitis, Bacteraemia, Sepsis
- Trial name
- PCV1103 (NCT01619462)
- Testing
- Prevenar 13 and Synflorix
- Where
- Papua New Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Malaria in Pregnancy, Sexually Transmitted Infections
Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea
The purpose of this study is to determine whether repeated courses of sulphadoxine-pyrimethamine (SP) in combination with azithromycin given at Antenatal Clinic, leads to lower rates of low birth weight deliveries (<2.5 kg) among…
- Conditions
- Malaria in Pregnancy, Sexually Transmitted Infections, Anaemia
- Trial name
- IPTp in PNG (NCT01136850)
- Testing
- chloroquine, sulphadoxine pyrimethamine, LLIN, azithromycin, sulphadoxine pyrimethamine, LLIN
- Where
- Papua New Guinea
- Volunteers
- 2,793 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Immune Tolerance
Pneumococcal Conjugate Vaccine Followup
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to potential immunological hypo-responsiveness (i.e. a poorer immune response to repeat vaccination).
- Trial name
- PCVFU (NCT01414504)
- Testing
- Prevenar + PPV, Infant PCV (Prevenar) + PPV at 9 months, No Prevenar + PPV at 9 months
- Where
- Papua New Guinea
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- William Pomat